Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 8/2015

01-08-2015 | Research Article

Androgen receptor promotes esophageal cancer cell migration and proliferation via matrix metalloproteinase 2

Authors: Yi Zhang, Tiecheng Pan, Xiaoxuan Zhong, Cai Cheng

Published in: Tumor Biology | Issue 8/2015

Login to get access

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide. Androgen receptor (AR) plays an important role in many kinds of cancers. However, the molecular mechanisms of AR in ESCC are poorly characterized. In the present study, Western blot analysis and real-time quantitative PCR were performed to identify differentially expressed AR in 40 ESCC tissue samples, which revealed that the messenger RNA (mRNA) and protein expression of AR is upregulated in the ESCC tissue samples. AR overexpression induced increases in ESCC cell invasion and proliferation in vitro. Silencing of AR inhibited the proliferation of KYSE450 cells which have a relatively high level of AR, and the invasion of KYSE450 cells was distinctly suppressed. Furthermore, AR knockdown led to substantial reductions in matrix metalloproteinase 2 (MMP2) and p-AKT levels in ESCC cell lines, but no significant change in AKT and MMP9 expression. These results suggest that AR is involved in tumor progression, and thus, AR could represent selective targets for the molecularly targeted treatments of ESCC.
Literature
1.
Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45.CrossRefPubMed
2.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed
3.
4.
Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, et al. Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96:2839–48.CrossRefPubMedPubMedCentral
5.
Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92–5.CrossRefPubMed
6.
Rosato A, Pivetta M, Parenti A, Iaderosa GA, Zoso A, et al. Survivin in esophageal cancer: an accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer. 2006;119:1717–22.CrossRefPubMed
7.
Chen PJ, Yeh SH, Liu WH, Lin CC, Huang HC, Chen CL, et al. Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology. 2012;56(2):632–43.CrossRefPubMed
8.
Ha S, Ruoff R, Kahoud N, Franke TF, Logan SK. Androgen receptor levels are upregulated by Akt in prostate cancer. Endocr Relat Cancer. 2011;18(2):245–55.CrossRefPubMedPubMedCentral
9.
Ou Y, Liu L, Xue L, Zhou W, Zhao Z, Xu B, et al. TRAP1 shows clinical significance and promotes cellular migration and invasion through STAT3/MMP2 pathway in human esophageal squamous cell cancer. J Genet Genomics. 2014;41(10):529–37.CrossRefPubMed
10.
Uraoka N, Oue N, Sakamoto N, Sentani K, Oo HZ, Naito Y, et al. NRD1, which encodes nardilysin protein, promotes esophageal cancer cell invasion through induction of MMP2 and MMP3 expression. Cancer Sci. 2014;105(1):134–40.CrossRefPubMed
11.
Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002;60 Suppl 1:132–9.CrossRefPubMed
12.
Zhang BG, Du T, Zang MD, Chang Q, Fan ZY, Li JF, et al. Androgen receptor promotes gastric cancer cell migration and invasion via AKT-phosphorylation dependent upregulation of matrix metalloproteinase 9. Oncotarget. 2014;5(21):10584–95.CrossRefPubMedPubMedCentral
13.
Ma WL, Lai HC, Yeh S, Cai X, Chang C. Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis. Endocr Relat Cancer. 2014;21(3):R165–82.CrossRefPubMedPubMedCentral
14.
Slattery ML, Sweeney C, Murtaugh M, Ma KN, Caan BJ, Potter JD, et al. Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer. Int J Cancer. 2006;118(12):3140–6.CrossRefPubMed
15.
Yerramilli-Rao P, Garofalo O, Whatley S, Leigh PN, Gallo JM. Androgen-controlled specific gene expression in neuroblastoma cells. J Neurol Sci. 1995;129(Suppl):131–5.CrossRefPubMed
16.
Tihan T, Harmon JW, Wan X, Younes Z, Nass P, Duncan KL, et al. Evidence of androgen receptor expression in squamous and adenocarcinoma of the esophagus. Anticancer Res. 2001;21(4B):3107–14.PubMed
17.
Yamashita Y, Hirai T, Mukaida H, Kawano K, Toge T, Niimoto M, et al. Detection of androgen receptors in human esophageal cancer. Jpn J Surg. 1989;19(2):195–202.CrossRefPubMed
18.
Matsuoka H, Sugimachi K, Ueo H, Kuwano H, Nakano S, Nakayama M. Sex hormone response of a newly established squamous cell line derived from clinical esophageal carcinoma. Cancer Res. 1987;47(15):4134–40.PubMed
19.
Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25(1):9–34.CrossRefPubMed
Metadata
Title
Androgen receptor promotes esophageal cancer cell migration and proliferation via matrix metalloproteinase 2
Authors
Yi Zhang
Tiecheng Pan
Xiaoxuan Zhong
Cai Cheng
Publication date
01-08-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3257-x

Other articles of this Issue 8/2015

Tumor Biology 8/2015 Go to the issue

Research Article

Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast

Research Article

Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis

Retraction Note

Retraction Note to: Calcium/calmodulin-dependent kinase inhibitor induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells

Research Article

RETRACTED ARTICLE: MiR-335 acts as a potential tumor suppressor miRNA via downregulating ROCK1 expression in hepatocellular carcinoma

Research Article

Transcriptome meta-analysis reveals dysregulated pathways in nasopharyngeal carcinoma

Research Article

Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits